Skip to content

Clinical trials

Completed Granulomatosis with Polyangiitis trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Granulomatosis with Polyangiitis Status: Completed Country / region: United States Clear all

32 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20021
20031
20051
20061
20081
20101
20112
20122
20133
20143
20153
20181
20191

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed32

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Allergy and Infectious Diseases (NIAID)12
University of Pennsylvania7
University of South Florida6
Cambridge University Hospitals NHS Foundation Trust1
Genentech, Inc.1
Hoffmann-La Roche1
Human Genome Sciences Inc., a GSK Company1
Massachusetts General Hospital1
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)1
National Institutes of Health Clinical Center (CC)1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Granulomatosis with Polyangiitis32
Vasculitis20
Microscopic Polyangiitis15
Churg-Strauss Syndrome7
Giant Cell Arteritis7
Polyarteritis Nodosa7
Takayasu Arteritis7
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis6
Behcet Syndrome6
IgA Vasculitis5

Trials

Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.